Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

Objectives This post hoc analysis evaluated change from baseline (Δ) in weight/body mass index (BMI) and association with disease activity or lipid changes in tofacitinib‐treated patients with rheumatoid arthritis (RA). Methods Data up to month 12 were pooled from eight phase 3 and 3b/4 studies of p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jürgen Wollenhaupt, Jacques Morel, Claire Daien, Adeline Ruyssen‐Witrand, Cédric Lukas, Christophe Richez, Andrea Shapiro, Douglass S. Chapman, Magali Cros, Jose L. Rivas, Gustavo Citera
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Series:	ACR Open Rheumatology
Online Access:	https://doi.org/10.1002/acr2.70040
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Tofacitinib Citrate for Ulcerative Keratitis in a Patient with Rheumatoid Arthritis
by: Philip B. Meadow, et al.
Published: (2014-01-01)

Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
by: Caterina Vacchi, et al.
Published: (2021-01-01)

Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease
by: Claire Rempenault, et al.
Published: (2024-02-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy
by: N. A. Lapkina, et al.
Published: (2021-12-01)

Whole‐Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib
by: Chiara Bellocchi, et al.
Published: (2025-07-01)

Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data
by: Ali Ekin, et al.
Published: (2024-11-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
by: Adeline Ruyssen-Witrand, et al.
Published: (2019-02-01)

Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation
by: Katy Diallo, et al.
Published: (2025-05-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis—Real-Life Clinical Data
by: Vladimira Boyadzhieva, et al.
Published: (2025-05-01)

The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis
Published: (2016-10-01)

Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib
by: Yu. V. Muraviev, et al.
Published: (2019-09-01)

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
by: Peter Nash, et al.
Published: (2019-06-01)

Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis
by: Chunyan Zhu, et al.
Published: (2025-06-01)

Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis
by: Enikő Sebestyén, et al.
Published: (2025-04-01)

Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study
by: Bernard Combe, et al.
Published: (2024-09-01)

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
by: G. A. Markova, et al.
Published: (2022-10-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis
by: Jiwei Zhao, et al.
Published: (2025-04-01)

Synthesis and in vitro evaluation of novel pH-triggered biocompatible folate-chondroitin sulfate-dexamethasone copolymers for delivery of tofacitinib in rheumatoid arthritis
by: Zahra Ansarypour, et al.
Published: (2025-05-01)

Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"
by: YanRan Qiu, et al.
Published: (2025-03-01)

A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials
by: Grace C. Wright, et al.
Published: (2025-03-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Successful use of tofacitinib in reactive arthritis following COVID-19 infection
by: Prasanta Padhan, et al.
Published: (2023-01-01)

Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis
by: E. V. Chetina, et al.
Published: (2021-06-01)

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
by: Adeline Ruyssen-Witrand, et al.
Published: (2025-01-01)

Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis
by: Adeline Ruyssen-Witrand, et al.
Published: (2024-02-01)

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
by: A. E. Karateev, et al.
Published: (2021-09-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Tofacitinib as an adjuvant treatment for pediatric Still's disease
by: Ling Hou, et al.
Published: (2025-08-01)

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib
by: Parvin Mansouri, et al.
Published: (2025-06-01)